Here we propose an "integrative sequencing approach" utilizing a 1500 gene exome comparative analysis between multiple myeloma or related plasma cell malignancies and normal cells coupled to capture transcriptome sequencing to provide a nearly comprehensive landscape of the genetic alterations for the purpose of identifying informative and/or actionable mutations in patients with multiple myeloma and plasma cell malignancies. The approach will enable the detection of point mutations, insertions/deletions, gene fusions and rearrangements, amplifications/deletions, and outlier expressed genes among other classes of alterations.
Clinical-grade Molecular Profiling of Patients With Multiple Myeloma and Related Plasma Cell Malignancies
Patients must have a diagnosis of multiple myeloma or related malignancy
Patients are undergoing standard of care bone marrow aspirates
Patients (male or female) from any race or ethnicity must be at least 18 years of age at the time of registration.
Procedure-specific signed informed consent form prior to initiation of any study-related procedures.
You CAN'T join if...
It is the enrolling study physician's discretion to decide if a patient is not fit enough to undergo a bone marrow aspirate.
Patients who are incarcerated are not eligible to participate.
Women who are pregnant
Patients who have had another malignancy within the last five (5) years (except for basal or squamous cell carcinoma, or in situ cancer of the cervix) where there is a possibility to contaminate the bone marrow aspirate.
UCSF Medical Centeraccepting new patients San Francisco, California, 94143, United States
City of Hopeaccepting new patients Duarte, California, 91010, United States